Edaravone-sodium ozagrel (thromboxane A2 synthase inhibitor) comparative post-marketing study on acute ischemic stroke

Trial Profile

Edaravone-sodium ozagrel (thromboxane A2 synthase inhibitor) comparative post-marketing study on acute ischemic stroke

Completed
Phase of Trial: Phase IV

Latest Information Update: 14 Jan 2013

At a glance

  • Drugs Edaravone (Primary) ; Ozagrel
  • Indications Embolism and thrombosis; Stroke
  • Focus Therapeutic Use
  • Acronyms EDO
  • Most Recent Events

    • 10 Nov 2009 Actual number of patients (401) added as reported by ClinicalTrials.gov.
    • 27 Dec 2007 Status changed from in progress to completed.
    • 28 Aug 2006 Status change
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top